ArticleBMC oral health2025
Cyclooxygenase-2 expression in advanced oral squamous cell carcinoma: a biomarker of poor prognosis.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThe primary aim of this study was to evaluate the impact of cyclooxygenase-2 (COX-2) expression on overall survival (OS), local recurrence-free survival (LRFS), and regional recurrence-free survival (RRFS) in patients diagnosed with advanced oral squamous cell carcinoma (AOSCC). MATERIALS AND
methodsCOX-2 expression levels were assessed in 191 cases of AOSCC and 50 cases of normal mucosa using immunohistochemistry (IHC). Comparisons were made between COX-2 expression in AOSCC and normal mucosal tissues, as well as its influence on OS, LRFS, and RRFS. The Cancer Genome Atlas (TCGA)- Head and Neck Squamous Cell Carcinoma (HNSC) database was utilized for validation.
resultsIn this cohort of 191 patients with AOSCC followed for 1-145 months (median: 68.3 months), AOSCC Patients exhibited significantly higher COX-2 expression compared to normal oral mucosa tissues. Consistent result was obtained from analysis of the AOSCC subgroup from TCGA HNSC cohort. In the subset of AOSCC patients filtered from the TCGA-HNSC database, COX-2 mRNA expression showed no statistically significant association with survival. However, In our cohort of AOSCC patients from IHC analysis, COX-2 expression emerged as an independent prognostic factor for OS, LRFS, and RRFS. Positive COX-2 expression was associated with a markedly increased risk of recurrence and diminished survival outcomes.
conclusionsCOX-2 is overexpressed in AOSCC and appears to be a potential adverse prognostic factor in our cohort. As a biomarker, COX-2 may offer valuable prognostic insights for AOSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.